Evaluation of TB elimination strategies in Canadian Inuit populations: Nunavut as a case study.
92B05
Agent-based simulation 2000 MSC
Inuit populations
Treatment
Tuberculosis
Journal
Infectious Disease Modelling
ISSN: 2468-0427
Titre abrégé: Infect Dis Model
Pays: China
ID NLM: 101692406
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
21
06
2022
accepted:
26
07
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Tuberculosis (TB) continues to disproportionately affect Inuit populations in Canada with some communities having over 300 times higher rate of active TB than Canadian-born, non-Indigenous people. Inuit Tuberculosis Elimination Framework has set the goal of reducing active TB incidence by at least 50% by 2025, aiming to eliminate it by 2030. Whether these goals are achievable with available resources and treatment regimens currently in practice has not been evaluated. We developed an agent-based model of TB transmission to evaluate timelines and milestones attainable in Nunavut, Canada by including case findings, contact-tracing and testing, treatment of latent TB infection (LTBI), and the government investment on housing infrastructure to reduce the average household size. The model was calibrated to ten years of TB incidence data, and simulated for 20 years to project program outcomes. We found that, under a range of plausible scenarios with tracing and testing of 25%-100% of frequent contacts of detected active cases, the goal of 50% reduction in annual incidence by 2025 is not achievable. If active TB cases are identified rapidly within one week of becoming symptomatic, then the annual incidence would reduce below 100 per 100,000 population, with 50% reduction being met between 2025 and 2030. Eliminating TB from Inuit populations would require high rates of contact-tracing and would extend beyond 2030. The findings indicate that time-to-identification of active TB is a critical factor determining program effectiveness, suggesting that investment in resources for rapid case detection is fundamental to controlling TB.
Identifiants
pubmed: 36313153
doi: 10.1016/j.idm.2022.07.005
pii: S2468-0427(22)00056-2
pmc: PMC9583452
doi:
Types de publication
Journal Article
Langues
eng
Pagination
698-708Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
None declared.
Références
Epidemics. 2017 Dec;21:39-47
pubmed: 28641948
Clin Infect Dis. 2007 Sep 15;45(6):715-22
pubmed: 17712755
BMC Infect Dis. 2019 Oct 24;19(1):890
pubmed: 31651260
CMAJ. 2013 Mar 5;185(4):287-8
pubmed: 23382256
Ann Intern Med. 2008 Nov 18;149(10):689-97
pubmed: 19017587
Clin Infect Dis. 2019 Jun 18;69(1):159-166
pubmed: 30383204
PLoS Med. 2009 Sep;6(9):e1000146
pubmed: 19753109
Int J Tuberc Lung Dis. 1999 Oct;3(10):847-50
pubmed: 10524579
Am J Respir Crit Care Med. 2006 Apr 15;173(8):922-6
pubmed: 16474028
Am J Respir Crit Care Med. 2009 Sep 1;180(5):475-80
pubmed: 19542475
N Engl J Med. 2011 Jul 7;365(1):11-20
pubmed: 21732833
Sci Rep. 2018 Mar 29;8(1):5382
pubmed: 29599463
Infect Drug Resist. 2018 Jun 12;11:873-887
pubmed: 29928135
Trans R Soc Trop Med Hyg. 2014 Aug;108(8):474-81
pubmed: 24970276
PLoS One. 2019 Dec 27;14(12):e0226507
pubmed: 31881023
Am Rev Respir Dis. 1992 Jan;145(1):36-41
pubmed: 1731596
Stat Med. 2017 Jul 20;36(16):2522-2532
pubmed: 28370491
PLoS One. 2019 Oct 22;14(10):e0223966
pubmed: 31639145
PLoS One. 2017 Mar 14;12(3):e0173411
pubmed: 28291800
BMC Public Health. 2017 Jan 13;17(1):73
pubmed: 28086846
Can Commun Dis Rep. 2018 Mar 01;44(3-4):82-85
pubmed: 31007615
CMAJ. 2011 Apr 19;183(7):741-3
pubmed: 21324868
Int J Tuberc Lung Dis. 2004 Apr;8(4):392-402
pubmed: 15141729
PLoS One. 2013 Sep 04;8(9):e72470
pubmed: 24023742
Can Commun Dis Rep. 2017 Mar 02;43(3-4):67-71
pubmed: 29770067
PLoS One. 2011;6(6):e20755
pubmed: 21738585
BMC Public Health. 2022 May 23;22(1):1032
pubmed: 35606703
Med Clin (Barc). 1998 Oct 10;111(11):401-4
pubmed: 9834911
CMAJ. 2000 Jul 25;163(2):157-8
pubmed: 10934973
N Engl J Med. 1997 Sep 18;337(12):801-8
pubmed: 9295239
Int J Epidemiol. 2011 Aug;40(4):964-70
pubmed: 21441552
Ann Intern Med. 2008 Aug 5;149(3):177-84
pubmed: 18593687
PLoS One. 2015 Mar 03;10(3):e0118457
pubmed: 25734772
Int J Circumpolar Health. 2020 Dec;79(1):1758501
pubmed: 32379538
N Engl J Med. 2004 May 13;350(20):2060-7
pubmed: 15141044
Scand J Infect Dis. 2011 Jul;43(6-7):424-9
pubmed: 21332285
PLoS One. 2021 Mar 22;16(3):e0248493
pubmed: 33750959
Indian Dermatol Online J. 2012 Jan;3(1):2-6
pubmed: 23130251